Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21890225.
- Also identified by DOI 10.1016/j.radonc.2011.07.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75 mg/m(2) gemcitabine once a week, concurrently with standard radiotherapy of 60 Gy/6 weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further studies.
Medical subject headings
- Antimetabolites, Antineoplastic
- Carcinoma, Transitional Cell
- Chemoradiotherapy
- Deoxycytidine
- Urinary Bladder Neoplasms